Tests MK-2870 alone or with other drugs for gastrointestinal cancers
Tests MK-2870 in adults with advanced bowel, pancreas or bile duct cancer.
Plain-language title generated from the registry record
Registry title: A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Key facts
- Where
- Beijing, Changsha, Chengdu, Fuzhou, Shanghai, and Wuhan, ChinaSee the 6 sites
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced colorectal, pancreatic or biliary tract cancer that cannot be removed by surgery. It tests MK-2870 alone or with other treatments.
- Age
- 18 years or older
- Sex
- Men and women can join
- Disease stage
- Unresectable or metastatic colorectal cancer; advanced or metastatic pancreatic ductal adenocarcinoma (PDAC); advanced and/or unresectable biliary tract cancer (BTC)
- Earlier treatment
- Colorectal cancer and PDAC: must have had earlier cancer treatment. Biliary tract cancer: both people who have and have not had earlier treatment can join. Anyone with earlier treatment must have recovered from its side effects.
Main reasons for not taking part
- History of severe eye disease
- Earlier systemic cancer treatment, including trial drugs, within 4 weeks before starting the study treatment
- History of pneumonitis or interstitial lung disease (ILD) that needed steroids
- Current pneumonitis or ILD
- Suspected pneumonitis or ILD that standard tests at screening cannot rule out
Read by machine on 12 November 2026.
Where in China
- Beijing Cancer hospital-Digestive Oncology (Site 0061)Beijing, ChinaContact: Toll Free NumberNo longer taking part
- Hunan Cancer Hospital-intervention department (Site 0066)Changsha, ChinaContact: Toll Free NumberNo longer taking part
- West China Hospital, Sichuan University (Site 0068)Chengdu, ChinaContact: Study CoordinatorTaking people
- The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army (Site 0063)Fuzhou, ChinaContact: Study CoordinatorTaking people
- Renji Hospital Shanghai Jiao Tong University School of Medicine-Oncology Department (Site 0067)Shanghai, ChinaContact: Toll Free NumberNo longer taking part
- Wuhan Union Hospital Cancer Center. (Site 0064)Wuhan, ChinaContact: Toll Free NumberNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Merck Sharp & Dohme LLC
- Trial code
- NCT06428409EU 2023-508703-21-00
- Record updated
- 29 October 2026
- Original description
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn:Read full original descriptionShow less
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn:
* About the safety of sacituzumab tirumotecan alone or with other treatments and if people tolerate it * How many people have the cancer respond (get smaller or go away) to treatment
Inclusion: The main inclusion criteria include but are not limited to the following:; Has one of the following cancers:; Unresectable or metastatic colorectal cancer and has received prior therapy for the cancer; Advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) and has received prior therapy for the cancer; Advanced and/or unresectable biliary tract cancer (BTC) and has received prior therapy for the cancer; Advanced and/or unresectable BTC and has not received prior therapy for the cancer; For participants who have received prior therapy for cancer: Has recovered from any side effects due to previous cancer treatment.
Exclusion: For participants who have received prior therapy for cancer: Received prior systemic anticancer therapy including investigational agents within 4 weeks before starting study intervention; History of severe eye disease; History of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening; The main exclusion criteria include but are not limited to the following:.